Cinzia Finocchi

Savona, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 70 publications

Correction: Real‑World Response and Super‑Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study.

Correction: Real‑World Response and Super‑Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study.

Journal: Neurology and therapy

Published: July 23, 2026

Is achieving higher standards in real-world migraine care feasible with anti-CGRP monoclonal antibodies preventive therapies?: Insights from the EUREkA cohort.

Is achieving higher standards in real-world migraine care feasible with anti-CGRP monoclonal antibodies preventive therapies?: Insights from the EUREkA cohort.

Journal: Cephalalgia : an international journal of headache

Published: June 19, 2026

Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort.

Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort.

Journal: Neurology

Published: May 27, 2026

Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study.

Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study.

Journal: Neurology and therapy

Published: March 18, 2026

Building bridges in migraine management: consensus pathways on best practices across primary and specialist care in Italy.

Building bridges in migraine management: consensus pathways on best practices across primary and specialist care in Italy.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Published: February 05, 2026

Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort.

Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort.

Journal: Neurology

Published: January 28, 2026

Evolving care pathways for women with migraine in Italy: results from a national survey.

Evolving care pathways for women with migraine in Italy: results from a national survey.

Journal: Frontiers in neurology

Published: November 27, 2025

Profiling the real-world migraine patient: public health insights from sociodemographic, lifestyle, and clinical data in the Italian National Migraine Registry (I-GRAINE).

Profiling the real-world migraine patient: public health insights from sociodemographic, lifestyle, and clinical data in the Italian National Migraine Registry (I-GRAINE).

Journal: The journal of headache and pain

Published: July 28, 2025

Three-year treatment with anti-CGRP monoclonal antibodies modifies migraine course: the prospective, multicenter I-GRAINE study.

Three-year treatment with anti-CGRP monoclonal antibodies modifies migraine course: the prospective, multicenter I-GRAINE study.

Journal: Journal of neurology

Published: December 08, 2024

Cut-Off Values Able to Identify Migraine Patients With Increased Pressure-Pain Sensitivity Independent of the Migraine Cycle Through a Single Assessment: A Secondary Analysis of a Multicentre, Cross-Sectional, Observational Study.

Cut-Off Values Able to Identify Migraine Patients With Increased Pressure-Pain Sensitivity Independent of the Migraine Cycle Through a Single Assessment: A Secondary Analysis of a Multicentre, Cross-Sectional, Observational Study.

Journal: European journal of pain (London, England)

Published: September 01, 2024

Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study.

Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study.

Journal: Neurology and therapy

Published: August 06, 2024

The "central vein sign" to differentiate multiple sclerosis from migraine.

The "central vein sign" to differentiate multiple sclerosis from migraine.

Journal: Headache

Published: June 19, 2024

Showing 1-12 of 70

Last Updated: 09/26/2026